155488-25-8

Usage

Uses

Used in Pharmaceutical Industry:
N-[(3R)-1-(3,3-Dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea is used as a pharmaceutical compound for its potential therapeutic properties. The specific application reason is not provided in the materials, but given its chemical structure, it may have potential uses in the development of drugs targeting various medical conditions.
Used in Research and Development:
In the field of research and development, N-[(3R)-1-(3,3-Dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea may be used as a starting material or a tool to study the effects of its chemical structure on biological activity. The application reason is to explore its potential interactions with biological targets and to understand its pharmacological properties, which could lead to the discovery of new therapeutic agents.
Used in Gastric Carcinoids Treatment:
As mentioned in the provided materials, Sograzepide, which shares a similar chemical structure, is used in the treatment of gastric carcinoids or patients with chronic atrophic gastritis. Therefore, N-[(3R)-1-(3,3-Dimethyl-2-oxobutyl)-2,3-dihydro-2-oxo-5-(2-pyridinyl)-1H-1,4-benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea may also be used as a gastric receptor antagonist for similar applications.

Upstream product

• 186086-59-9 [1-(3,3-Dimethyl-2-oxo-butyl)-2-oxo-5-pyridin-2-yl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 164343-31-1 (R)-3-Amino-1-(3,3-dimethyl-2-oxo-butyl)-5-pyridin-2-yl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 
• 168162-32-1 3-[N-(tert-butoxycarbonyl)-N-methyl-amino]phenyl isocyanate 
• 168162-30-9 3-(N-tert-butoxycarbonyl-N-methyl-amino)-benzoic acid 
• 168162-22-9 (3RS)-Amino-1-(tert-butylcarbonylmethyl)-2,3-dihydro-5-(pyridin-2-yl)-1H-1,4-benzodiazepin-2-one 
• 152665-84-4 1,3-dihydro-5-(pyridin-2-yl)-3(R,S)-[(benzyloxycarbonyl)-amino]-2H-1,4-benzodiazepin-2-one 
• 111331-82-9 3-[(tert-butoxycarbonyl)amino]benzoic acid 
• 99-05-8 meta-aminobenzoic acid 
• 42471-56-7 2-(2-aminobenzoyl)pyridine 

Relevant academic research and scientific papers

(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)- 1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist

A number of new 1,4-benzodiazepin-2-one-based gastrin/CCK-B receptor antagonists related to the archetypal analogue L-365,260, and more closely to the recently reported compound YM022, have been synthesized and evaluated for biological activity. The compounds were screened for their ability to inhibit the binding of [125I]CCK-8 to gastrin/CCK-B receptors prepared from rat brains and that of [3H]L-364,718 to CCK-A receptors from rat pancreas, and were shown to be potent and selective ligands for the gastrin/CCK-B receptor. Functional studies in vivo demonstrated the compounds to be antagonists of the receptor as evidenced by their ability to inhibit pentagastrin-induced gastric acid secretion in anesthetized rats. More extensive evaluation in viva included determination of ED50 values in the rat acid secretion model for selected compounds and an examination of the effect of these compounds on pentagastrin-induced gastric acid secretion in Heidenhain pouch dogs following oral and intravenous administration. Two compounds, i.e. (3R)-N- [1-[(tert-butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4- benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea, 15c (YF476), and (3R)-N- [1-[(tert-Butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4- benzodiazepin-3-yl]-N'-[3-(dimethylamino)phenyl]urea hydrochloride, 15d, showed potent dose-dependent effects in both models with the former showing excellent oral bioavailability and an ED50 of 21 nmol/kg po in dogs. 15e is currently under clinical investigation for the treatment of gastro-oesophagal reflux disease (GORD).

Benzodiazepine derivatives useful as CCK-receptor antagonists

This invention relates to benzodiazepine derivatives which are useful as drugs exhibiting antagonism at the gastrin and/or CCK-B receptor, and to their production.